Sugi Predict

Sugi Predict / Compounds / SCHEMBL4396699

SCHEMBL4396699

SCHEMBL4396699

CC[C@H](C)[C@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1cccc(O)c1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](N)CC(C)C)C(O)C(C)C)C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)O)C(O)C(=O)O)[C@H](C)O

nearest known ligand 0.51

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ OPRM1 P35372 1/20 0.51
▸ OPRD1 P41143 1/20 0.51
▸ OPRK1 P41145 1/20 0.51
▸ VIPR2 P41587 5/20 0.48
▸ VIPR1 P32241 3/20 0.48
▸ ECE1 P42892 1/20 0.47
▸ GLP1R P43220 1/20 0.47
▸ MUS81 Q96NY9 1/20 0.47
▸ KISS1R Q969F8 5/20 0.47
▸ NPY1R P25929 2/20 0.46
▸ NPY2R P49146 2/20 0.46
▸ NPY4R P50391 2/20 0.46
▸ NPY5R Q15761 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4396809 0.93 OPRM1 (0.47) OPRM1OPRD1OPRK1VIPR2VIPR1
SCHEMBL4401001 0.92 OPRM1 (0.45) OPRM1OPRD1OPRK1VIPR2VIPR1
SCHEMBL13220268 0.92 OPRM1 (0.53) OPRM1OPRD1OPRK1KISS1RNPY1R
SCHEMBL4403948 0.90 OPRM1 (0.47) OPRM1OPRD1OPRK1VIPR2VIPR1
SCHEMBL4088852 0.89 KISS1R (0.52) OPRM1OPRD1OPRK1VIPR2VIPR1
SCHEMBL4082449 0.89 OPRM1 (0.51) OPRM1OPRD1OPRK1VIPR2VIPR1
SCHEMBL2367081 0.88 OPRM1 (0.55) OPRM1OPRD1OPRK1VIPR2VIPR1
SCHEMBL4412998 0.88 OPRM1 (0.46) OPRM1OPRD1OPRK1VIPR2VIPR1
SCHEMBL4400894 0.88 OPRM1 (0.47) OPRM1OPRD1OPRK1VIPR2VIPR1
SCHEMBL4406897 0.88 OPRM1 (0.46) OPRM1OPRD1OPRK1VIPR2VIPR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105119-A1 ASPARAGINE-10-SUBSTITUTED NONADEPSIPEPTIDES BAYER SCHERING PHARMA AG (DE) 2009-04-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105119-A1 ASPARAGINE-10-SUBSTITUTED NONADEPSIPEPTIDES ASNS, DNPEP, ANPEP OPRM1 3788/4885OPRD1 3240/4885OPRK1 3793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.